| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/30/2003 | WO2002064116A3 Thermolabile liposome with controlled release temperature |
| 01/30/2003 | WO2002056825A3 Composition and method to increase calcium levels in animals |
| 01/30/2003 | WO2002055136A3 Intrasvascular drug delivery device and use therefor |
| 01/30/2003 | WO2002055101A3 Storage stable powder compositions of interleukin-4 receptor |
| 01/30/2003 | WO2002055056A3 Local use of essential oils for treating herpes labialis |
| 01/30/2003 | WO2002053097A3 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 01/30/2003 | WO2002049573A3 Novel in-situ forming controlled release microcarrier delivery system |
| 01/30/2003 | WO2002034200A3 Transdermal therapeutic systems comprising photosensitive active substances |
| 01/30/2003 | WO2002030394A3 Medicinal aerosol formulations |
| 01/30/2003 | WO2002026215A3 Thermogelling biodegradable aqueous polymer solution |
| 01/30/2003 | WO2002014876A3 Test unit and method for the production of stable formulations |
| 01/30/2003 | WO2002009865A1 Production of polyelectrolyte capsules by surface precipitation |
| 01/30/2003 | WO2002002745A3 Method and system for consistent and effective encapsulation of biological material |
| 01/30/2003 | WO2001089477A3 Controlled release of materials from polymer matrices |
| 01/30/2003 | US20030023337 Manufacturing method |
| 01/30/2003 | US20030023091 For therapy and prophylaxis of peptic ulcers, gastro intestinal inflammatory diseases like duodenal/ gastric ulcer or gastritis or other gastro intestinal disorders |
| 01/30/2003 | US20030022944 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/30/2003 | US20030022942 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/30/2003 | US20030022940 Novel pharmaceutical formulations of modafinil |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022928 Particle size distribution such that the median value of the volume mean diameter is between 450-700; blocking angiotensin II receptors, hypotensive agents and treating congestive heart failure and renal failure |
| 01/30/2003 | US20030022922 Tablet, without excessive stickiness or tablet punch residue |
| 01/30/2003 | US20030022921 Stable pharmaceutical formulation comprising torsemide modification II |
| 01/30/2003 | US20030022912 Rapid-onset medicament for treatment of sexual dysfunction |
| 01/30/2003 | US20030022910 Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine |
| 01/30/2003 | US20030022894 Imidazotriazinone-containing compositions for nasal administration |
| 01/30/2003 | US20030022880 Soluble forms of amoxicillin and treatment of animals |
| 01/30/2003 | US20030022877 Method of increasing testosterone and related steroid concentrations in women |
| 01/30/2003 | US20030022861 Delivery of genetic material via solution of dextrin derivatives; gene therapy; immunotherapy |
| 01/30/2003 | US20030022856 Method for sustained release local delivery of drugs for ablation of unwanted tissue |
| 01/30/2003 | US20030022855 Melanoma differentiation associated gene-5 (mda-5) nucleic acids, proteins, and gene promoters for induction of apoptotic cell death |
| 01/30/2003 | US20030022854 Vaccines using nucleic acid-lipid complexes |
| 01/30/2003 | US20030022852 Biodegradable immunomodulatory formulations and methods for use thereof |
| 01/30/2003 | US20030022846 Coating material is specifically degraded inside phagocytic mammalian cell infected with microorganism to allow release of compound within infected cell |
| 01/30/2003 | US20030022828 A growth factor formulation comprising: a polypeptide of the TGF- beta (tranformation growth factor) superfamily, N-vinyl-2-pyrrolidone polymer carrier and a solvent selected from water and aqueous buffer solutions |
| 01/30/2003 | US20030022802 Comprising 1,1,1,3,3- pentafluorobutane, water, and a hydrocarbon selected from n-pentane, isopentane, cyclopentane, n-hexane, and isohexane |
| 01/30/2003 | US20030022379 Method for preparing closed vesicles |
| 01/30/2003 | US20030022359 Transgenic algae for delivering antigens to an animal |
| 01/30/2003 | US20030022242 Particle for use in the absorption of one or more materials in preferential environments |
| 01/30/2003 | US20030022161 Diagnosing mammary gland cancer in humans; obtain ductal fluid sample, monitor marker gene product expression, amplified concentrations of marker products indicates cancer |
| 01/30/2003 | US20030022149 Enhanced production of safe plasma preparations |
| 01/30/2003 | US20030022147 Solutions for use as plasma expanders and substitutes |
| 01/30/2003 | US20030021881 Mixture containing lecithin; homogeneity solid matrix |
| 01/30/2003 | US20030021854 Nanocrystal microbiocide metal |
| 01/30/2003 | US20030021848 Supplying to arteries at time of angioplasty |
| 01/30/2003 | US20030021846 Sustained release; wet granulation, compaction |
| 01/30/2003 | US20030021845 Gastroretentive controlled release pharmaceutical dosage forms |
| 01/30/2003 | US20030021844 Immediate-release oral pellet comprising polyglycolysed glycerides, and manufacturing process |
| 01/30/2003 | US20030021843 Antidiabetic preparation for oral administration |
| 01/30/2003 | US20030021842 Means for creating a mass having structural integrity |
| 01/30/2003 | US20030021841 Metformin hydrochloride; blending, compression |
| 01/30/2003 | US20030021840 High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same |
| 01/30/2003 | US20030021839 Capsules |
| 01/30/2003 | US20030021838 Anticancer agents; vaccines; induction immunology response |
| 01/30/2003 | US20030021837 Mixture of lecithin, phosphatides, sterol and drugs |
| 01/30/2003 | US20030021836 Magnesium di-potassium EDTA complex and method of administration |
| 01/30/2003 | US20030021835 Medical patch with burstable partition |
| 01/30/2003 | US20030021830 Compressible powder |
| 01/30/2003 | US20030021829 Removal eye dryness; adsorption polyvinylpyrrolidone |
| 01/30/2003 | US20030021828 Method for treating and/or preventing retinal diseases with substained release corticosteroids |
| 01/30/2003 | US20030021822 Method and apparatus for treating obesity and for delivering time-released medicaments |
| 01/30/2003 | US20030021821 Collagen or collagen-like peptide containing polymeric matrices |
| 01/30/2003 | US20030021820 Dissolvable oxides for biological applications |
| 01/30/2003 | US20030021794 Heat shock protein-based vaccines and immunotherapies |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021778 Ocular treatment by topical application of an immunoglobulin |
| 01/30/2003 | US20030021767 Recombinant p53 adenovirus methods and compositions |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | US20030021752 Administering lipophilic drug through mucous membranes |
| 01/30/2003 | DE19943553C2 Zusammensetzung, insbesondere Pflegebalsam Composition, particularly balm |
| 01/30/2003 | CA2457308A1 Controlled drug delivery systems providing variable release rates |
| 01/30/2003 | CA2457304A1 Zero order controlled drug delivery system |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2454200A1 Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| 01/30/2003 | CA2453993A1 Method and composition for treatment of cancer |
| 01/30/2003 | CA2453959A1 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
| 01/30/2003 | CA2453720A1 A salt/ion pair medicinal aerosol formulation |
| 01/30/2003 | CA2453616A1 Pharmaceutical preparations containing ion exchange resins charged with active ingredients |
| 01/30/2003 | CA2453473A1 Water-free ubichinon concentrate |
| 01/30/2003 | CA2453342A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 01/30/2003 | CA2453290A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | CA2452556A1 Protein-containing foodstuff comprising a coss-linking enzyme and a hydrocolloid |
| 01/30/2003 | CA2452357A1 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | CA2448724A1 2-methyl-thieno-benzodiazepine lyophilized formulation |
| 01/29/2003 | EP1279682A1 Amphiphilic biodegradable block copolymers and self-assembled polymer aggregates formed from the same in aqueous milieu |
| 01/29/2003 | EP1279406A1 Transporters and drug delivery system by using the same |
| 01/29/2003 | EP1279403A1 Pernasally absorbable insulin preparations |
| 01/29/2003 | EP1279402A1 Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules |
| 01/29/2003 | EP1279401A1 Oil in water emulsions containing saponins |
| 01/29/2003 | EP1279400A1 Modifying the fatty acid composition of cell membranes of organs and tissues |
| 01/29/2003 | EP1278829A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 01/29/2003 | EP1278818A2 Low ionic strength ophthalmic compositions |
| 01/29/2003 | EP1278795A1 Azeotrope-like compositions of pentafluoropropane and water |
| 01/29/2003 | EP1278591A1 Mixing apparatus |
| 01/29/2003 | EP1278551A2 Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| 01/29/2003 | EP1278549A2 Cyclodextrin containing glycopeptide antibiotic compositions |
| 01/29/2003 | EP1278546A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
| 01/29/2003 | EP1278524A1 Medical combinations comprising mometasone and salmeterol |